Cargando…

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial

AIMS: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial assessed once-weekly exenatide (EQW) vs. placebo, added to usual care in 14,752 patients with type 2 diabetes mellitus (Clinicaltrials.gov: NCT01144338). We assessed the lifetime cost-effectiveness of adding EQW vs. usual care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becker, Frauke, Dakin, Helen A., Reed, Shelby D., Li, Yanhong, Leal, José, Gustavson, Stephanie M., Wittbrodt, Eric, Hernandez, Adrian F., Gray, Alastair M., Holman, Rury R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Scientific Publishers 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844554/ https://www.ncbi.nlm.nih.gov/pubmed/34813910 http://dx.doi.org/10.1016/j.diabres.2021.109152

Ejemplares similares

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
por: Mentz, Robert J., et al.
Publicado: (2018)

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2020)

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020)

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
por: Clegg, Lindsay E., et al.
Publicado: (2019)

Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data
por: Leal, Jose, et al.
Publicado: (2020)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
por: Dakin, Helen A., et al.
Publicado: (2020)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double‐blind, placebo‐controlled trial
por: Leal, José, et al.
Publicado: (2022)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data
por: Dakin, Helen A., et al.
Publicado: (2020)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
por: Grossman, Samuel S.
Publicado: (2014)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann, Katherine V, et al.
Publicado: (2014)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
por: Pencek, R, et al.
Publicado: (2012)

Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial
por: Yammine, Luba, et al.
Publicado: (2018)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
por: Chiquette, Elaine, et al.
Publicado: (2012)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
por: Klausen, Mette Kruse, et al.
Publicado: (2022)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
por: Deng, Wuquan, et al.
Publicado: (2015)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
por: Taylor, Kristin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ucl9kpljfdlfnhgr86g8t7eh97